HMGB1, TLR and RAGE: a functional tripod that leads to diabetic inflammation

Bibliography

• Nogueira-Machado JA, Chaves MM. From hyperglycemia to AGE–RAGE interaction on the cell surface: a dangerous metabolic route for diabetic patients. Expert Opin Ther Targets 2008;12:871-82
   PubMed Web of Science ®Google Scholar
• Wild S, Roglic G, Green A, Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53
   PubMed Web of Science ®Google Scholar
• Rauvala H, Rouhiainen A. RAGE as a receptor of HMGB1 (Amphoterin): roles in health and disease. Curr Mol Med 2007;7:725-34
   PubMed Web of Science ®Google Scholar
• Kim JJ, Sears DD. TLR4 and insulin resistance. Gastroenterol Res Pract 2010;2010:1-11
   Web of Science ®Google Scholar
• Bastard JP, Pieroni L, Hainque B. Relationship between plasma plasminogen activator inhibitor 1 and insulin resistance. Diabetes Metab Res Rev 2000;16:192-201
   PubMed Web of Science ®Google Scholar
• Muller S, Martin S, Koenig W, Impaired glucose tolerance is associated with increased serum concentrations of interleukin 6 and co-regulated acute-phase proteins but not TNF-alpha or its receptors. Diabetologia 2002;45:805-12
   PubMed Web of Science ®Google Scholar
• Pickup JC, Crook MA. Crook, Is type 2 diabetes mellitus a disease of the innate immune system? Diabetologia 1998;41:1241-8
   PubMed Web of Science ®Google Scholar
• Syed MA, Barinas-Mitchell E, Pietropaolo SL, Is type 2 diabetes a chronic inflammatory/autoimmune disease? Diabetes Nutr Metab 2002;15:68-83
   PubMedGoogle Scholar
• Tracey KJ. Fat meets the cholinergic antiinflammatory pathway. J Exp Med 2005;202:1017-21
   PubMed Web of Science ®Google Scholar
• Klune JR, Dhupar R, Cardinal J, HMGB1: endogenous danger signaling. Mol Med 2008;14:476-84
   PubMed Web of Science ®Google Scholar
• Mantell LL, Parrish WR, Ulloa L. Hmgb-1 as a therapeutic target for infectious and inflammatory disorders. Shock 2006;25:4-11
   PubMed Web of Science ®Google Scholar
• Basta G, Schmidt AM, De Caterina R. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res 2004;63:582-92
   PubMed Web of Science ®Google Scholar
• Dasu MR, Devaraj S, Ling Z, High glucose induces Toll-like receptor expression in human monocytes: mechanism of activation. Diabetes 2008;57:3090-8
   PubMed Web of Science ®Google Scholar
• Han J, Zong J, Wei W, Extracellular high-mobility group box 1 acts as an innate immune mediator to enhance autoimmune progression and diabetes onset in NOD mice. Diabetes 2008;57:2118-27
   PubMed Web of Science ®Google Scholar
• Matsuoka N, Itoh T, Watari H, High-mobility group box 1 is involved in the initial events of early loss of transplanted islets in mice. J Clin Invest 2010;120:735-43
   Google Scholar
• Agresti A, Bianchi ME. HMGB proteins and gene expression. Curr Opin Genet Dev 2003;13:170-8
   PubMed Web of Science ®Google Scholar
• Bustin M. Chromatin unfolding and activation by HMGN* chromosomal proteins. Trends Biochem Sci 2001;26:431-7
   PubMed Web of Science ®Google Scholar
• Thomas JO. HMG1 and 2: architectural DNA-binding proteins. Biochem Soc Trans 2001;29:395-401
   PubMed Web of Science ®Google Scholar
• Li J, Kokkola R, Tabibzadeh S, Structural basis for the proinflammatory cytokine activity of high mobility group box 1. Mol Med 2003;9:37-45
   PubMed Web of Science ®Google Scholar
• Messmer D, Yang H, Telusma G, High mobility group box protein 1: an endogenous signal for dendritic cell maturation and Th1 polarization. J Immunol 2004;173:307-13
   PubMed Web of Science ®Google Scholar
• Yang H, Ochani M, Li J, Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci USA 2004;101:296-301
   PubMed Web of Science ®Google Scholar
• Yang H, Hreggvidsdottir HS, Palmblad K, A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. Proc Natl Acad Sci USA 2010;107:11942-7
   PubMed Web of Science ®Google Scholar
• Bell CW, Jiang W, Reich CF, The extracellular release of HMGB1 during apoptotic cell death. Am J Physiol Cell Physiol 2006;291:C1318-25
   PubMed Web of Science ®Google Scholar
• Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 2005;5:331-42
   PubMed Web of Science ®Google Scholar
• Rovere-Querini P, Capobianco A, Scaffidi P, HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep 2004;5(8):825-30
   PubMed Web of Science ®Google Scholar
• Pisetsky DS, Erlandsson-Harris H, Andersson U. High-mobility group box protein 1 (HMGB1): an alarmin mediating the pathogenesis of rheumatic disease. Arthritis Res Ther 2008;10:209
   PubMed Web of Science ®Google Scholar
• Bonaldi T, Talamo F, Scaffidi P, Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J 2003;22:5551-60
   PubMed Web of Science ®Google Scholar
• Devaraj S, Dasu MR, Park SH, Increased levels of ligands of Toll-like receptors 2 and 4 in type 1 diabetes. Diabetologia 2009;52:1665-8
   PubMed Web of Science ®Google Scholar
• Pachydaki SI, Tari SR, Lee SE, Upregulation of RAGE and its ligands in proliferative retinal disease. Exp Eye Res 2006;82(5):807-15
   PubMed Web of Science ®Google Scholar
• Dasu MR, Devaraj S, Park S, Increased toll-like receptor (TLR) activation and TLR ligands in recently diagnosed type 2 diabetic subjects. Diabetes Care 2010;33:861-8
   PubMed Web of Science ®Google Scholar
• Hagiwara S, Iwasaka H, Hasegawa A, Effects of hyperglycemia and insulin therapy on high mobility group box 1 in endotoxin-induced acute lung injury in a rat model. Crit Care Med 2008;36:2407-13
   PubMed Web of Science ®Google Scholar
• Park JS, Gamboni-Robertson F, He Q, High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol 2006;290:C917-24
   PubMed Web of Science ®Google Scholar
• Park JS, Svetkauskaite D, He Q, Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 2004;279:7370-7
   PubMed Web of Science ®Google Scholar
• van Beijnum JR, Buurman WA, Griffioen AW. Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1). Angiogenesis 2008;11:91-9
   PubMed Web of Science ®Google Scholar
• van Zoelen MA, Yang H, Florquin S, Role of toll-like receptors 2 and 4, and the receptor for advanced glycation end products in high-mobility group box 1-induced inflammation in vivo. Shock 2009;31:280-4
   PubMed Web of Science ®Google Scholar
• Branco-Madeira F, Lambrecht BN. Lambrecht, High mobility group box-1 recognition: the beginning of a RAGEless era? EMBO Mol Med 2010;2:193-5
   PubMed Web of Science ®Google Scholar
• Kokkola R, Andersson A, Mullins G, RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages. Scand J Immunol 2005;61:1-9
   PubMed Web of Science ®Google Scholar
• Park JS, Arcaroli J, Yum HK, Activation of gene expression in human neutrophils by high mobility group box 1 protein. Am J Physiol Cell Physiol 2003;284:C870-9
   PubMed Web of Science ®Google Scholar
• Huttunen HJ, Fages C, Rauvala H. Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J Biol Chem 1999;274:19919-24
   PubMed Web of Science ®Google Scholar
• Li J, Wang H, Mason JM, Recombinant HMGB1 with cytokine-stimulating activity. J Immunol Methods 2004;289:211-23
   PubMed Web of Science ®Google Scholar
• Rouhiainen A, Tumova S, Valmu L, Pivotal advance: analysis of proinflammatory activity of highly purified eukaryotic recombinant HMGB1 (amphoterin). J Leukoc Biol 2007;81:49-58
   PubMed Web of Science ®Google Scholar
• Sha Y, Zmijewski J, Xu Z, HMGB1 develops enhanced proinflammatory activity by binding to cytokines. J Immunol 2008;180:2531-7
   PubMed Web of Science ®Google Scholar
• Youn JH, Oh YJ, Kim ES, High mobility group box 1 protein binding to lipopolysaccharide facilitates transfer of lipopolysaccharide to CD14 and enhances lipopolysaccharide-mediated TNF-alpha production in human monocytes. J Immunol 2008;180:5067-74
   PubMed Web of Science ®Google Scholar
• Zimmermann K, Volkel D, Pable S, Native versus recombinant high-mobility group B1 proteins: functional activity in vitro. Inflammation 2004;28:221-9
   PubMed Web of Science ®Google Scholar
• Yan SD, Schmidt AM, Anderson GM, Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 1994;269:9889-97
   PubMed Web of Science ®Google Scholar
• Andersson U, Wang H, Palmblad K, High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 2000;192:565-70
   PubMed Web of Science ®Google Scholar
• Andrassy M, Volz HC, Igwe JC, High-mobility group box-1 in ischemia-reperfusion injury of the heart. Circulation 2008;117:3216-26
   PubMed Web of Science ®Google Scholar
• Bruchfeld A, Qureshi AR, Lindholm B, High Mobility Group Box Protein-1 correlates with renal function in chronic kidney disease (CKD). Mol Med 2008;14:109-15
   PubMed Web of Science ®Google Scholar
• Crook M. Type 2 diabetes mellitus: a disease of the innate immune system? An update. Diabet Med 2004;21:203-7
   PubMed Web of Science ®Google Scholar
• Kolb H, Mandrup-Poulsen T. An immune origin of type 2 diabetes? Diabetologia 2005;48:1038-50
   PubMed Web of Science ®Google Scholar
• Zarember KA, Godowski PJ. Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J Immunol 2002;168:554-61
   PubMed Web of Science ®Google Scholar
• Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006;124:783-801
   PubMed Web of Science ®Google Scholar
• Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002;20:197-216
   PubMed Web of Science ®Google Scholar
• Lin L. RAGE on the Toll Road? Cell Mol Immunol 2006;3:351-8
   PubMed Web of Science ®Google Scholar
• Devaraj S, Dasu MR, Rockwood J, Increased toll-like receptor (TLR) 2 and TLR4 expression in monocytes from patients with type 1 diabetes: further evidence of a proinflammatory state. J Clin Endocrinol Metab 2008;93:578-83
   PubMed Web of Science ®Google Scholar
• Tobias PS, Curtiss LK. Toll-like receptors in atherosclerosis. Biochem Soc Trans 2007;35:1453-5
   PubMed Web of Science ®Google Scholar
• Buraczynska M, Baranowicz-Gaszczyk I, Tarach J, Toll-like receptor 4 gene polymorphism and early onset of diabetic retinopathy in patients with type 2 diabetes. Hum Immunol 2009;70:121-4
   PubMed Web of Science ®Google Scholar
• Shi H, Kokoeva MV, Inouye K, TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 2006;116:3015-25
   PubMed Web of Science ®Google Scholar
• Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004;4:499-511
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Takeda K. Current views of toll-like receptor signaling pathways. Gastroenterol Res Pract 2010;2010:240365
   PubMed Web of Science ®Google Scholar
• Burns K, Martinon F, Esslinger C, MyD88, an adapter protein involved in interleukin-1 signaling. J Biol Chem 1998;273:12203-9
   PubMed Web of Science ®Google Scholar
• Wesche H, Henzel WJ, Shillinguaw W, MyD88: an adapter that recruits IRAK to the IL-1 receptor complex. Immunity 1997;7:837-47
   PubMed Web of Science ®Google Scholar
• Fitzgerald KA, Palsson-McDermott EM, Bowie AG, Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction. Nature 2001;413:78-83
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Sato S, Mori K, Cutting edge: a novel Toll/IL-1 receptor domain-containing adapter that preferentially activates the IFN-beta promoter in the Toll-like receptor signaling. J Immunol 2002;169:6668-72
   PubMed Web of Science ®Google Scholar
• Fitzgerald KA, Rowe DC, Barnes BJ, LPS-TLR4 signaling to IRF-3/7 and NF-kappaB involves the toll adapters TRAM and TRIF. J Exp Med 2003;198:1043-55
   PubMed Web of Science ®Google Scholar
• Carty M, Goodbody R, Schroder M, The human adaptor SARM negatively regulates adaptor protein TRIF-dependent Toll-like receptor signaling. Nat Immunol 2006;7:1074-81
   PubMed Web of Science ®Google Scholar
• Kumar A, Periyannan GR, Narayanan B, Experimental evidence for a metallohydrolase mechanism in which the nucleophile is not delivered by a metal ion: EPR spectrokinetic and structural studies of aminopeptidase from Vibrio proteolyticus. Biochem J 2007;403:527-36
   PubMed Web of Science ®Google Scholar
• Kawai T, Adachi O, Ogawa T, Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity 1999;11:115-22
   PubMed Web of Science ®Google Scholar
• Kawai T, Takeuchi O, Fujita T, Lipopolysaccharide stimulates the MyD88-independent pathway and results in activation of IFN-regulatory factor 3 and the expression of a subset of lipopolysaccharide-inducible genes. J Immunol 2001;167:5887-94
   PubMed Web of Science ®Google Scholar
• Rassa JC, Meyers JL, Zhang Y, Murine retroviruses activate B cells via interaction with toll-like receptor 4. Proc Natl Acad Sci USA 2002;99:2281-6
   PubMed Web of Science ®Google Scholar
• Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997;388:394-7
   PubMed Web of Science ®Google Scholar
• Ojaniemi M, Liljeroos M, Harju K, TLR-2 is upregulated and mobilized to the hepatocyte plasma membrane in the space of Disse and to the Kupffer cells TLR-4 dependently during acute endotoxemia in mice. Immunol Lett 2006;102:158-68
   PubMed Web of Science ®Google Scholar
• Chow JC, Young DW, Golenbock DT, Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J Biol Chem 1999;274:10689-92
   PubMed Web of Science ®Google Scholar
• Byrd-Leifer CA, Block, EF, The role of MyD88 and TLR4 in the LPS-mimetic activity of Taxol. Eur J Immunol 2001;31:2448-57
   PubMed Web of Science ®Google Scholar
• Kawasaki K, Akashi S, Shimazu R, Mouse toll-like receptor 4. MD-2 complex mediates lipopolysaccharide-mimetic signal transduction by Taxol. J Biol Chem 2000;275:2251-4
   PubMed Web of Science ®Google Scholar
• Kawasaki K, Gomi K, Nishijima M. Cutting edge: Gln22 of mouse MD-2 is essential for species-specific lipopolysaccharide mimetic action of taxol. J Immunol 2001;166:11-14
   PubMed Web of Science ®Google Scholar
• Gallucci S, Matzinger P. Danger signals: SOS to the immune system. Curr Opin Immunol 2001;13:114-19
   PubMed Web of Science ®Google Scholar
• Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003;21:335-76
   PubMed Web of Science ®Google Scholar
• Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest 2005;115:1111-19
   PubMed Web of Science ®Google Scholar
• Aliprantis AO, Yang RB, Weiss DS, The apoptotic signaling pathway activated by Toll-like receptor-2. EMBO J 2000;19:3325-36
   PubMed Web of Science ®Google Scholar
• Brightbill HD, Libraty DH, Krutzik SR, Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors. Science 1999;285:732-6
   PubMed Web of Science ®Google Scholar
• Lien E, Sellati TJ, Yoshimura A, Toll-like receptor 2 functions as a pattern recognition receptor for diverse bacterial products. J Biol Chem 1999;274:33419-25
   PubMed Web of Science ®Google Scholar
• Lehner MD, Morath S, Michelsen KS, Induction of cross-tolerance by lipopolysaccharide and highly purified lipoteichoic acid via different Toll-like receptors independent of paracrine mediators. J Immunol 2001;166:5161-7
   PubMed Web of Science ®Google Scholar
• Schwandner R, Dziarski R, Wesche H, Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by toll-like receptor 2. J Biol Chem 1999;274:17406-9
   PubMed Web of Science ®Google Scholar
• Underhill DM, Ozinsky A, Smith KD, Toll-like receptor-2 mediates mycobacteria-induced proinflammatory signaling in macrophages. Proc Natl Acad Sci USA 1999;96:14459-63
   PubMed Web of Science ®Google Scholar
• Campos MA, Almeida IC, Takeuchi O, Activation of Toll-like receptor-2 by glycosylphosphatidylinositol anchors from a protozoan parasite. J Immunol 2001;167:416-23
   PubMed Web of Science ®Google Scholar
• Underhill DM, Ozinsky A, Hajjar AM, The Toll-like receptor 2 is recruited to macrophage phagosomes and discriminates between pathogens. Nature 1999;401:811-15
   PubMed Web of Science ®Google Scholar
• Opitz B, Schroder NWJ, Spreitzer I, Toll-like receptor-2 mediates Treponema glycolipid and lipoteichoic acid-induced NF-kappaB translocation. J Biol Chem 2001;276(25):22041-7
   PubMed Web of Science ®Google Scholar
• Massari P, Henneke P, Ho Y, Cutting edge: Immune stimulation by neisserial porins is toll-like receptor 2 and MyD88 dependent. J Immunol 2002;168(4):1533-7
   PubMed Web of Science ®Google Scholar
• Hirschfeld M, Weis JJ, Toshchakov V, Signaling by toll-like receptor 2 and 4 agonists results in differential gene expression in murine macrophages. Infect Immun 2001;69:1477-82
   PubMed Web of Science ®Google Scholar
• Werts C, Tapping RI, Mathison JC, Leptospiral lipopolysaccharide activates cells through a TLR2-dependent mechanism. Nat Immunol 2001;2:346-52
   PubMed Web of Science ®Google Scholar
• Arbibe L, Mira JP, Teusch N, Toll-like receptor 2-mediated NF-kappaB activation requires a Rac1-dependent pathway. Nat Immunol 2000;1:533-40
   PubMed Web of Science ®Google Scholar
• Aomatsu K, Kato T, Fujita H, Toll-like receptor agonists stimulate human neutrophil migration via activation of mitogen-activated protein kinases. Immunology 2008;123:171-80
   PubMed Web of Science ®Google Scholar
• Schmidt AM, Stern DM. RAGE: a new target for the prevention and treatment of the vascular and inflammatory complications of diabetes. Trends Endocrinol Metab 2000;11:368-75
   PubMed Web of Science ®Google Scholar
• Yonekura H, Yamamoto Y, Sakurai S, Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 2003;370:1097-109
   PubMed Web of Science ®Google Scholar
• Kislinger T, Fu C, Huber B, Nepsi-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem 1999;274(44):31740-9
   PubMed Web of Science ®Google Scholar
• Neeper M, Schmidt AM, Brett J, Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 1992;267:14998-5004
   PubMed Web of Science ®Google Scholar
• Bucciarelli LG, Wendt T, Rong L, RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease. Cell Mol Life Sci 2002;59:1117-28
   PubMed Web of Science ®Google Scholar
• Hofmann MA, Drury S, Hudson BI, RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response. Genes Immun 2002;3:123-35
   PubMed Web of Science ®Google Scholar
• Schmidt AM, Yan SD, Yan SF, The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001;108:949-55
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Kato I, Yonekura H, Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest 2001;108:261-8
   PubMed Web of Science ®Google Scholar
• Myint KM, Yamamoto Y, Doi T, RAGE control of diabetic nephropathy in a mouse model: effects of RAGE gene disruption and administration of low-molecular weight heparin. Diabetes 2006;55:2510-22
   PubMed Web of Science ®Google Scholar
• Yonekura H, Yakamoto Y, Sakurai S, Roles of the receptor for advanced glycation endproducts in diabetes-induced vascular injury. J Pharmacol Sci 2005;97:305-11
   PubMed Web of Science ®Google Scholar
• Soro-Paavonen A, Watson AMD, Li J, Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes 2008;57:2461-9
   PubMed Web of Science ®Google Scholar
• Hsieh HL, Schafer BW, Sasaki N, Expression analysis of S100 proteins and RAGE in human tumors using tissue microarrays. Biochem Biophys Res Commun 2003;307:375-81
   PubMed Web of Science ®Google Scholar
• Taguchi A, Blood DC, del Toro G, Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000;405:354-60
   PubMed Web of Science ®Google Scholar
• Yan SS, Wu ZY, Zhang HP, Suppression of experimental autoimmune encephalomyelitis by selective blockade of encephalitogenic T-cell infiltration of the central nervous system. Nat Med 2003;9:287-93
   PubMed Web of Science ®Google Scholar
• Ruan BH, Li X, Winkler AR, Complement C3a, CpG oligos, and DNA/C3a complex stimulate IFN-alpha production in a receptor for advanced glycation end product-dependent manner. J Immunol 2010;185:4213-22
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Harashima A, Saito H, Septic shock is associated with receptor for advanced glycation end products ligation of LPS. J Immunol 2011;186:3248-57
   PubMed Web of Science ®Google Scholar
• Yan SF, Ravichandran R, Naka Y, Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. Circ Res 2003;93:1159-69
   PubMed Web of Science ®Google Scholar
• Bierhaus A, Hofmann MA, Ziegler R, AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovasc Res 1998;37:586-600
   PubMed Web of Science ®Google Scholar
• Schmidt AM, Hori O, Cao R, RAGE: a novel cellular receptor for advanced glycation end products. Diabetes 1996;45(Suppl 3):S77-80
   Google Scholar
• Brett J, Schmidt AM, Yan SD, Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol 1993;143:1699-712
   PubMed Web of Science ®Google Scholar
• Yan SD, Chen X, Fu J, RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 1996;382:685-91
   PubMed Web of Science ®Google Scholar
• Cooke CL, Brockelsby JC, Baker PN, The receptor for advanced glycation end products (RAGE) is elevated in women with preeclampsia. Hypertens Pregnancy 2003;22:173-84
   PubMed Web of Science ®Google Scholar
• Lander HM, Tauras JM, Ogiste JS, Activation of the receptor for advanced glycation end products triggers a p21ras-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem 1997;272:17810-14
   PubMed Web of Science ®Google Scholar
• Sakaguchi T, Yan SF, Yan SD, Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest 2003;111:959-72
   PubMed Web of Science ®Google Scholar
• Hudson BI, Kalea AZ, Del Mar Arriero, Interaction of the RAGE cytoplasmic domain with diaphanous-1 is required for ligand-stimulated cellular migration through activation of Rac1 and Cdc42. J Biol Chem 2008;283:34457-68
   PubMed Web of Science ®Google Scholar
• Ramasamy R, Yan SF, Schmidt AM. RAGE: therapeutic target and biomarker of the inflammatory response-the evidence mounts. J Leukoc Biol 2009;86:505-12
   PubMed Web of Science ®Google Scholar
• Xu Y, Toure F, Qu W, Advanced glycation end product (AGE)-receptor for AGE (RAGE) signaling and up-regulation of Egr-1 in hypoxic macrophages. J Biol Chem 2010;285:23233-40
   PubMed Web of Science ®Google Scholar
• Bierhaus A, Nawroth PP. Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications. Diabetologia 2009;52:2251-63
   PubMed Web of Science ®Google Scholar
• Bierhaus A, Schiekofer S, Schwaninger M, Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes 2001;50:2792-808
   PubMed Web of Science ®Google Scholar
• Bierhaus A, Stern DM, Nawroth PP. RAGE in inflammation: a new therapeutic target? Curr Opin Investig Drugs 2006;7:985-91
   PubMed Web of Science ®Google Scholar
• Stern DM, Yan SD, Yan SF, Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes. Ageing Res Rev 2002;1:1-15
   PubMed Web of Science ®Google Scholar
• Bhattacharjee RN, Akira S. Toll-like receptor signaling: emerging opportunities in human diseases and medicine. Curr Immunol Rev 2005;1:81-90
   Google Scholar